Aureobasidium.org

patent 2023

Immune adjuvant – Japan (Patent No. 5242855)

Iwai A., Uchiyama H., Nagahara Y. · Japanese Patent Office
Research Archive
TL;DR — Key Findings
  • Japanese patent claims AP β-glucan as an immune adjuvant enhancing vaccine and immune therapy responses.
  • Adjuvant properties reflect AP-glucan's ability to boost and direct immune responses in combination use.
  • Vaccine adjuvant patent positions AP-glucan beyond supplement status into pharmaceutical applications.

Abstract

Immune adjuvant – Japan (Patent No. 5242855)

Patent Details

Country of RegistrationJapan

Patent No.No. 5242855Registration DateApril 12, 2013

Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) was tested as an “adjuvant” substance to further enhance the efficacy of the intranasal vaccine.The group that received the intranasal vaccine alone showed higher antibody titers for both IgA and IgG than the group that received the intranasal vaccine in combination with the Aureo culture medium.These results indicate that Aureo culture medium has an adjuvant effect for intranasal vaccines.Adjuvant : A substance that aids or enhances the effect of a vaccine.IgA : Antibody that exists in large quantities in mucous membranesIgG : Antibody that exists in large quantities in the serum

Summary

Summary

Background

This Japanese patent (Patent No. 5242855) covers Aureobasidium pullulans β-glucan as an immune adjuvant — an agent that enhances immune responses when co-administered with vaccines or other immunotherapeutic agents.

Key Findings

AP β-glucan's immune adjuvant properties are claimed for enhancing vaccine-induced immunity and immune therapy responses. The patent represents commercial recognition of AP-glucan's ability to boost and direct immune responses when used in combination with other immunological agents.

Relevance to Aureobasidium Beta Glucan Research

Patent protection for vaccine adjuvant applications positions AP-glucan as more than a dietary supplement — it represents pharmaceutical-grade application of its immunostimulatory properties. This supports AP-glucan's potential in vaccine development and immune therapy protocols.

Citation

Iwai A., Uchiyama H., Nagahara Y.. Immune adjuvant – Japan (Patent No. 5242855). Japanese Patent Office. 2023.

Study Details
Study Type
patent
Published
2023
Journal
Japanese Patent Office
Authors
Iwai A., Uchiyama H., Nagahara Y.
Important Notice

For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.